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Lenalidomide shows promise in CLL, mediating its anti-leukaemic effect through direct 
cytotoxicity, modulation of the tumour microenvironment and correction of functional defects in 
immune cells [1]. Lenalidomide is, however, associated with significant toxicity, especially when 
doses greater than 10mg/day are used [2-4]. We investigated the safety and tolerability of a 
relatively low dose of lenalidomide and hypothesised combination with dexamethasone would 
reduce toxicity, especially tumour lysis syndrome (TLS) and tumour flare reactions (TFR), whilst 
allowing for dose escalation and thereby improve responses. 
LenD was an open label phase II non-randomised multicentre trial conducted in the United 
Kingdom, approved by the NCRI CLL subgroup and funded by Celgene, who provided drug free of 
charge (RV-CLL-PI-0569).  
Treatment consisted of up to twelve 28-day cycles of oral dexamethasone (20mg/day, days 1-4), 
and lenalidomide (days 1-28), starting at 5mg/day in cycle 1 and escalating to 10mg/day in the 
absence of toxicity, if creatinine clearance was ≥ 50ml/min.  For those with a creatinine clearance of 
30-50 ml/min, lenalidomide was started at 2.5mg/day and escalated to 5mg/day. 
Eligible patients, aged 18 years or over, had to have relapsed or refractory CLL requiring 
treatment as defined by NCI-WG criteria [5], a life expectancy of more than 6 months and a WHO 
performance status of less than 2. Participants must have received at least one prior line of therapy 
and deemed unsuitable for fludarabine or alemtuzumab containing regimens. Local or systemic 
treatment for CLL, investigational therapy and major surgery were not permitted within 4 weeks of 
starting trial treatment. All participants gave informed consent and agreed to comply with the 
requirements of the Celgene Revlimid® Pregnancy Prevention Programme.  
Patients were reassessed every 4 weeks during treatment, and treatment was discontinued 
upon disease progression or for unacceptable toxicity. Lenalidomide was interrupted for any grade 
3-4 toxicity and recommenced at a dose 2.5mg lower than previously administered once toxicity had 
resolved to grade 1 or less. 
Patients were formally assessed for response 4 weeks after their last cycle of treatment. The 
primary endpoint was the proportion of patients who achieved an objective response (CR + PR) 
according to NCI-WG guidelines [5] and the proportion of patients suffering Common Terminology 
Criteria for Adverse Events (CTCAE v4.03) grade 3/4 toxicities.  Secondary endpoints were duration 
of response and time from study registration to next treatment. All patients who received trial 
treatment were included in the primary analysis. 
Twelve patients were recruited from 2 UK sites (University College London and Royal Liverpool 
University Hospitals) between November 2012 and May 2014. Despite initial enrolment in line with 
expectations, the trial was closed prematurely in December 2014 due to poor recruitment (target 
=24), which was impacted by the availability of new B cell receptor inhibitors (BCRi). All 12 patients 
were male, with a median age of 61.5 years (range 33-82) and had received a median of 5 prior lines 
of therapy (range 2-9) (Table 1). 
In total 62 cycles of lenalidomide and dexamethasone were delivered across the 12 patients. The 
median number of cycles completed per patient was 3.5, and only 3 patients managed to complete 
the full 12 cycles of trial treatment. The median daily dose of lenalidomide achieved across the 
entire cohort was 5mg. Only 5 patients reached 10mg/day, 4 of whom had subsequent dose 
reductions or omissions due to toxicity.  
Four patients (33.3%) stopped trial treatment early due to adverse events: the first due to renal 
toxicity likely related to lenalidomide but not TLS, the second due to febrile neutropenia, the third 
due to grade 3 and 4 neutropenia and thrombocytopenia respectively, and the fourth due to 
multiple side effects. Four (33.3%) patients stopped treatment due to evidence of disease 
progression. An additional patient showed evidence of progressive disease at the time of formal 
response assessment 13.7 months after registration. Of these patients the median time to next 
treatment was 6.6 months (range 0.9-15.2 months). 
Eleven patients (91.7%) experienced a grade 3 or higher adverse event during trial treatment 
(Table 2). The most common grade 3 or higher toxicities were thrombocytopenia (n=7, 58.3%) and 
neutropenia (n=6, 50.0%), with sepsis reported in 2 patients (16.7%). One patient (8.3%) developed 
thromboembolic disease. No patients developed TLS or TFR. There was one early death, within 50 
days of enrolment, due to a perforated sigmoid colon, possibly related to lenalidomide and 
dexamethasone. 
Three patients achieved a partial response, giving an overall response rate (ORR) of 25.0% (95% 
CI: 5.5-57.2%). A further two patients had stable disease. The three patients who achieved a partial 
response achieved median daily lenalidomide doses of 3.8mg, 2.5mg and 5.0mg. Two patients 
completed 12 cycles of treatment and were still alive and progression-free 18.5 and 16.4 months 
post-registration. The first was 66 years old, WHO performance status 0, with unmutated IgVH and 
del 13q14.3, who had three prior lines of therapy (FCR, Chlorambucil and Rituximab/Bendamustine). 
The second was 57 years old, WHO performance status 0, with unmutated IgVH and complex 
cytogenetics including del 17p and 11q, who had 5 prior lines of therapy (FC, 
Rituximab/Dexamethasone, Allogeneic stem cell transplant (ASCT) with Donor Lymphocyte Infusion 
(DLI), Rituximab/Dexamethasone, Rituximab/Bendamustine/Mitoxantrone). The third patient who 
had previously received 7 lines of prior therapy (Chlorambucil, Fludarabine, R-CHOP, radiotherapy, 
ESHAP, ASCT and Rituximab) achieved a partial response but completed only 3 cycles of treatment 
before stopping due to clinician discretion. He progressed and died 4.8 months and 16.0 months 
post-registration respectively. The only other patient who completed 12 cycles of treatment is alive 
19.4 months post-registration having progressed after 13.7 months. This patient was 69 years old, 
with unmutated IgVH and Del 17p13.1, WHO performance status 0, who had undergone five 
previous lines of therapy (FC, splenectomy, Rituximab and Dexamethasone, ASCT and 
Bendamustine/Mitoxantrone). There was no clear clinical or biochemical predictors of response in 
these 3 patients although low 2-microglobulin and presence of trisomy 12 have been shown to 
associate with long term response [6]. 
After a median follow-up of 18.5 months, 4 (33.3%) patients are alive without progression and 1 
(8.3%) patient  alive with progression. 7 (58.3%) patients have died, due to disease progression 
(n=5), infection (n=1) or perforated sigmoid colon (n=1). 
To our knowledge, this is the first study to report on the use of a combination lenalidomide and 
dexamethasone in relapsed/refractory CLL patients. Despite limited numbers of patients, it adds to 
the growing body of evidence on the use of lenalidomide in CLL.  We hypothesised combination of 
low dose lenalidomide and dexamethasone would establish safety and efficacy of this regimen and 
did not observe a single incidence of TLS or TFR. However, despite the relatively low doses of 
lenalidomide used, a high rate of both haematological and non-haematological toxicity was 
observed, in keeping with other studies. .  
The ORR of 25% in LenD is comparable with the 11-44% reported in other studies [2,3,7], 
although Chanan-Khan et al and Ferrajoli et al both used a higher starting dose of lenalidomide and 
achieved higher median doses. Our cohort of patients were heavily pre-treated (median 5 prior lines 
of therapy) and had high risk features such as 17p deletion, which is in keeping with other trials in 
the relapsed/refractory setting.  
Interestingly, four patients enrolled into LenD had received a prior ASCT, of whom 2 achieved a 
PR and 1 maintaining stable disease. Lenalidomide has been associated with graft versus leukaemia 
effect [8], although we saw no evidence of corresponding graft versus host disease, likely due to a 
long interval between ASCT and lenalidomide administration unlike other trials [9].  
High rates of toxicity prevented planned dose escalations and resulted in a relatively low median 
daily dose of lenalidomide, which may have limited efficacy, but it is unclear whether 
dexamethasone contributed to the toxicity profile.   Chen et al  reported a superior ORR of 74% with 
lenalidomide and dexamethasone [10], but this was in untreated patients, who generally have 
higher response rates, even with single agent lenalidomide [11-14]. However, when compared to 
chlorambucil in the front line setting, lenalidomide has lower response rates and higher toxicity and 
mortality (Chanan-Khan, et al 2017).  
In summary, our pilot study demonstrates lenalidomide combined with dexamethasone can 
provide some patients with durable responses, including following ASCT. However in this extensively 
pre-treated cohort, lenalidomide is associated with significant toxicity, even at low starting doses. 
Dexamethasone appears to reduce the risk of TLS and TFR but did not minimise overall toxicity or 
allow for dose escalation.  
Combination therapy with lenalidomide, including with anti-CD20 antibodies have reported 
higher ORR [15,16] and given the potential synergistic mode of action of lenalidomide and BCRi, 
novel combinations are warranted and currently under investigation (NCT01886859).( 
Although small molecule inhibitors such as Ibrutinib and Venetoclax have drastically altered 
management and improved outcomes in CLL, they are not curative. Lenalidomide may have a role 
for this high risk group of patients with refractory disease, especially as we are entering an era of not 
having been previously exposed to multiple cytotoxic and immunosuppressive regimens. .  
High levels of toxicity with lenalidomide necessitates stringent medical supervision, cautious 
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Table 1: Baseline patient characteristics 
  
  
 N = 12 
  
 Median (range) 
Age, years 61.5 (33 – 82) 
 
Sex n (%) 
    Female 0 (0.0) 
    Male 12 (100.0) 
WHO performance status  
    0 6 (50.0) 
    1 4 (33.3) 
    2 2 (16.7) 
IgVH mutational analysis  
    Mutated 0 (0.0) 
    Unmutated 9 (75) 
    Missing 3 (25) 
Chromosomal abnormalities  
    Trisomy 12 2 (16.7) 
    Del 13q14.3 5 (41.7) 
    Del 11q22.3 3 (25.0) 
    Del 17p13.1 7 (58.3) 
 
 
Previous lines of treatment 
 
Median (range) 
5 (2 – 9) 
Haematology  
    Haemoglobin, g/dl 11.9 (9.6 – 17.6) 
    Neutrophils, x109/l 5.9 (0.1 – 18.4) 
    WBC, x109/l 42.6 (2.4 – 167.3) 
    Lymphocytes, x109/l 33.4 (1.8 – 155.6) 
    Platelets, x109/l 117.5 (12.0 – 225.0) 
    Monocytes, x109/l 0.8 (0.0 – 3.9) 
  
Table 2: CTCAE Grade 3-4 adverse events by frequency  
 




Thrombocytopenia 7 (58.3) 
Neutropenia 6 (50.0) 
Anaemia 2 (16.7) 





Diarrhoea 1 (8.3) 
Colonic perforation 1 (8.3) 
Infections and infestations  
Bladder infection 1 (8.3) 
Lung infection 1 (8.3) 
Sepsis 2 (16.7) 
Upper respiratory infection 1 (8.3) 
Investigations  
Alanine aminotransferase increased 1 (8.3) 
Blood bilirubin increased 1 (8.3) 
Metabolism and nutrition disorders  
Hypernatremia 1 (8.3) 
Respiratory, thoracic & mediastinal disorders  
Dyspnoea 2 (16.7) 
Hiccups 1 (8.3) 
Renal & Urinary Disorders  
Renal & urinary disorder NOS 1 (8.3) 
Vascular disorders  
Thromboembolic event 1 (8.3) 
 
 
 
 
